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Abstract 
Objective—The E26 transformation-specific domain transcription factor Etv2/Etsrp/ER71 is a master 
regulator of vascular endothelial differentiation during vasculogenesis, although its later role in sprouting 
angiogenesis remains unknown. Here, we investigated in the zebrafish model a role for Etv2 and related 
E26 transformation-specific factors, Fli1a and Fli1b in developmental angiogenesis. 
Approach and Results—Zebrafish fli1a and fli1b mutants were obtained using transposon-mediated gene 
trap approach. Individual fli1a and fli1b homozygous mutant embryos display normal vascular patterning, 
yet the angiogenic recovery observed in older etv2 mutant embryos does not occur in embryos lacking 
both etv2 and fli1b. Etv2 and fli1b double-deficient embryos fail to form any angiogenic sprouts and show 
greatly increased apoptosis throughout the axial vasculature. In contrast, fli1a mutation did not affect the 
recovery of etv2 mutant phenotype. Overexpression analyses indicate that both etv2 and fli1b, but not 
fli1a, induce the expression of multiple vascular markers and of each other. Temporal inhibition of Etv2 
function using photoactivatable morpholinos indicates that the function of Etv2 and Fli1b during 
angiogenesis is independent from the early requirement of Etv2 during vasculogenesis. RNA-Seq analysis 
and chromatin immunoprecipitation suggest that Etv2 and Fli1b share the same transcriptional targets 
and bind to the same E26 transformation-specific sites. 
Conclusions—Our data argue that there are 2 phases of early vascular development with distinct 
requirements of E26 transformation-specific transcription factors. Etv2 alone is required for early 
vasculogenesis, whereas Etv2 and Fli1b function redundantly during late vasculogenesis and early 
embryonic angiogenesis. 
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Objective—The E26 transformation-specific domain transcription factor Etv2/Etsrp/ER71 is a 
master regulator of vascular endothelial differentiation during vasculogenesis, although its later 
role in sprouting angiogenesis remains unknown. Here, we investigated in the zebrafish model a 
role for Etv2 and related E26 transformation-specific factors, Fli1a and Fli1b in developmental 
angiogenesis.
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Approach and Results—Zebrafish fli1a and fli1b mutants were obtained using transposon-
mediated gene trap approach. Individual fli1a and fli1b homozygous mutant embryos display 
normal vascular patterning, yet the angiogenic recovery observed in older etv2 mutant embryos 
does not occur in embryos lacking both etv2 and fli1b. Etv2 and fli1b double-deficient embryos 
fail to form any angiogenic sprouts and show greatly increased apoptosis throughout the axial 
vasculature. In contrast, fli1a mutation did not affect the recovery of etv2 mutant phenotype. 
Overexpression analyses indicate that both etv2 and fli1b, but not fli1a, induce the expression of 
multiple vascular markers and of each other. Temporal inhibition of Etv2 function using 
photoactivatable morpholinos indicates that the function of Etv2 and Fli1b during angiogenesis is 
independent from the early requirement of Etv2 during vasculogenesis. RNA-Seq analysis and 
chromatin immunoprecipitation suggest that Etv2 and Fli1b share the same transcriptional targets 
and bind to the same E26 transformation-specific sites.
Conclusions—Our data argue that there are 2 phases of early vascular development with 
distinct requirements of E26 transformation-specific transcription factors. Etv2 alone is required 
for early vasculogenesis, whereas Etv2 and Fli1b function redundantly during late vasculogenesis 
and early embryonic angiogenesis.
Keywords
angiogenesis; ETS transcription factor; vasculogenesis; zebrafish
The vertebrate vasculature forms early in development to support the metabolic needs of the 
developing embryo. The first blood vessels arise de novo from mesodermally derived 
endothelial precursors called angioblasts through vasculogenesis.1,2 Growth, expansion, and 
remodeling of the primary vasculature into a mature vascular network occur through the 
sprouting or longitudinal division of pre-existing vessels, termed angiogenesis.3,4 
Angiogenesis remains important throughout adulthood during tissue repair,5,6 estrus and 
pregnancy,7,8 and during muscle growth with exercise.9,10 Effective therapeutic control of 
angiogenic potential remains a critical unmet goal in the treatment of pathologies of hyper-
vascularization (eg, cancer and macular degeneration)11-14 and in situations requiring 
increased blood flow to ischemic tissues (eg, coronary heart disease, peripheral arterial 
disease, and wound healing disorders). 15-18 A key difficulty associated with antiangiogenic 
strategy design is that although many of the individual molecules required for the vertebrate 
vascular development and maintenance have been identified, the signaling cascades 
underlying these phenomena remain poorly understood because of a high degree of 
functional redundancy and overlapping target specificities. The functional overlap known to 
exist among the E26 transformation-specific (ETS) family of transcription factors is of 
particular interest because several vascular-specific ETS factors sit atop transcriptional 
hierarchies and thus represent potential therapeutic targets. 19-21
The ETS domain transcription factor Etv2/Etsrp has been identified as a critical regulator of 
embryonic vasculogenesis, with functional orthologs identified in multiple vertebrates, 
including zebrafish, Xenopus, mice (ER71/ETV2), and humans (ETV2).22-27 Like other ETS 
factors, Etv2/Etsrp contains a conserved 85-amino acid ETS domain that binds to a core 
GGA(A/T) motif to transcriptionally activate downstream target genes. Murine Etv2 binds 
synergistically with FoxC2 to activate the expression of a variety of endothelial genes (eg, 
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VegfR2/flkl, tie2, and cdh5).28 In zebrafish and in mice, etv2 is expressed during early 
somitogenesis in the lateral plate mesoderm (LPM) and later restricted to the vascular 
endothelium. Etv2 null mice and zebrafish lack a formed vasculature, do not achieve 
circulation, and die during embryogenesis.22,25,26,29
A related vascular endothelial–specific ETS factor, FLI1, has received significant research 
focus because translocations between the ETS domain of FLI1 and the transactivation 
domain of exchange web services generate an aberrant transcriptional activator leading to 
Ewing sarcoma.30,31 In Xenopus embryos, loss of Fli1 results in a substantial reduction in 
the number of hemangioblasts,32 suggesting that Fli1 is required for early hemangioblast 
specification and the subsequent formation of the blood and endothelial lineages. Mutant 
mice similarly display a deficit in the number of both blood and endothelial cells, and 
although the vasculature initially seems normal in these mutants, they hemorrhage from the 
dorsal aorta and ventricles of the brain and die by E12.5 because of endothelial cell 
apoptosis.33,34 Fli1 is induced by Etv2 during early mouse embryogenesis and subsequently 
maintains its own expression and the expression of other vascular markers through a positive 
autoregulatory feedback mechanism.34 However, the role of Fli1 during vasculogenesis and 
the initial stages of angiogenesis have not been established.
The zebrafish (Danio rerio) has emerged as an important vertebrate system for studying 
vasculogenesis and angiogenesis because of the optical transparency, rapid external 
embryonic development, and high fecundity. Zebrafish have 2 closely related FLI1 paralogs, 
fli1a and fli1b. Fli1a and Fli1b share 55% identity and thus exhibit greater sequence 
homology with each other than either does with Etv2 (which shares 14% identity with Fli1b 
and 16% with Fli1a; http://uswest.ensembl.org). Both are initially expressed in the LPM and 
later restricted to the vascular endothelium.35-37Overexpression of wild-type (WT) zebrafish 
Fli1a did not induce ectopic vascular marker expression, whereas a constitutively active 
VP16-fused form of Fli1a was shown to induce several hemangioblast markers, including 
etv2 and kdrl.32 Far less is known about the role played by fli1b, although it contains a 
predicted ETS-binding domain and thus potentially regulates a similar subset of ETS-target 
genes. Fli1b is located ≈4.2 kb downstream of etv2 on chromosome 16 and is transcribed in 
the opposite direction, mirroring the arrangement of ets1 and fli1a on zebrafish chromosome 
18 and of Ets1 and Fli1 in mice and humans.22,37 Interestingly, related fish species including 
stickleback and medaka also share similar arrangement of etv2 and fli1b genes, whereas in 
most other vertebrates, a single Fli1 homolog is located adjacent to Ets1 gene and not 
Etv2.23,38 Previously, combined morpholino (MO) knockdown of all 4 of these ETS factors 
(fli1a, fli1b, etv2, and ets1) in zebrafish was shown to result in a complete absence of 
angiogenic sprouting.29 By contrast, knockdown of fli1a or fli1b individually resulted in 
minor sprouting defects, suggesting that ≥1 of these ETS factors have redundant function. 
However, only limited phenotypic analysis of vascular defects has been performed, and the 
specific role of each ETS factor remains unclear. Furthermore, specificity of the observed 
phenotypes (except for etv2 MO) has not been demonstrated by RNA rescue or mutant 
confirmation. Recent studies have called into question many MO-based phenotypes, 
including Ets1 knockdown, which were not recapitulated in genetic mutants.39
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In this study, we isolated genetic fli1a and fli1b zebrafish mutants that were homozygous 
viable and displayed no apparent angiogenic defects, suggesting that at least some of the 
previously reported defects29 were caused by MO off-target effects. We demonstrate that 
Etv2 and Fli1b function together as regulators of vasculogenesis and angiogenesis. 
Combined loss of Etv2 and Fli1b, but not Etv2 and Fli1a, blocks the angiogenic recovery 
otherwise observed in etv2 mutants and results in increased endothelial cell apoptosis 
throughout the LPM. Overexpression analyses indicate that both etv2 and fli1b induce the 
expression of multiple vascular endothelial markers and of each other. Finally, RNA-Seq, 
chromatin immunoprecipitation, and fluorescent reporter assays indicate that Fli1b, similar 
to Etv2, is capable of regulating the expression of multiple vascular endothelial markers and 
that Fli1a is a potential direct transcriptional target of Fli1b. Taken together, our data 
indicate that fli1b is induced by Etv2 during early vasculogenesis and later acts redundantly 
with Etv2 to support late vasculogenesis and early developmental angiogenesis. 
Furthermore, our data provide critical mechanistic insight into the combinatorial roles 
played by ETS factors in vascularization of the developing embryo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Etv2/etsrp Mutant and Morphant Embryos Exhibit Late-Stage, Aberrant Sprouting 
Angiogenesis
Although etsrp/etv2y11 null mutants (henceforth referred to as etv2-/- and morphants exhibit 
strong defects in vasculogenesis before 24 hours post fertilization (hpf),22,29 they undergo a 
partial recovery of the intersegmental vessels (ISVs) by sprouting angiogenesis at later 
stages. To understand what promotes this recovery, we analyzed vascular development in 
etv2-/- embryos ranging in age from the 9-somite stage (13.5 hpf) through 72 hpf (Figure 1). 
Etv2-/- embryos lacked detectable fli1a:GFP expression in the anterior or posterior LPM at 
the 9-somite stage (Figure 1A and 1B), consistent with previous reports, indicating that etv2 
is both necessary and sufficient for initiating early vascular endothelial marker expression 
(eg, fli1a).22 The first indication of vascular recovery in etv2-/- embryos came at the 15-
somite stage (16 hpf) with the appearance of a posterior pool of fli1a:GFP+ cells (Figure 1D, 
arrow). Fli1a:GFP+ vascular progenitor cells remained disorganized, and vasculogenesis 
was impaired in 24 hpf etv2-/- mutants relative to WT embryos, resulting in a complete 
absence of lumenized axial vessels, ISV sprouts, or blood circulation (Figure 1F). At 36 hpf, 
arterial and venous boundaries were poorly defined and lumenized segments were largely 
absent in etv2-/- embryos (Figure 1H), yet intermittent ISV sprouts were observed extending 
from the dorsal boundary of the loosely organized fli1a:GFP+ pool of vascular endothelial 
progenitors. By 48 hpf, small segments of the dorsal aorta and posterior cardinal vein in 
etv2-/- embryos appeared lumenized, particularly in the tail, although mutant embryos never 
achieved circulation (Figure 1J). At 72 hpf (Figure 1L), the mutant vascular bed contained 
several full-length ISVs and a discontinuous dorsal longitudinal anastomotic vessel, 
although the majority of ISVs remained mispatterned. A similar recovery was observed in 
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etv2 morphant embryos (Figure 3A-3D). The etv2 morpholino has been validated in multiple 
previous studies22,27,40 and results in the same vascular phenotype as etv2-/- null mutants 
(Figures 1 and 3A-3D).
Angiogenic Recovery in etv2-Deficient Embryos Is Mediated by Existing Vascular 
Endothelial Cells Rather Than a Latent Population of Progenitor Cells
To properly interpret the basis of the recovery of etv2-deficient embryos, the source of cells 
contributing to this recovery needed to be determined. We used the photoconvertible 
TgBAC(etv2:Kaede) line that specifically labels angioblasts and their daughter (ie, 
differentiated) vascular endothelial cells (VECs) to identify populations of VECs arising 
before and after key stages of the observed recovery. Using this approach, VECs present 
before photoconversion exhibit both red and green fluorescence, whereas those arising later 
seem green only. Etv2 morpholino MO1 inhibits translation of Etv2 protein but is designed 
to not affect etv2:Kaede reporter expression, which allows observation of vascular 
endothelial progenitors in etv2 morphant embryos. Etv2:Kaede embryos injected with etv2 
morpholino exhibited a partial impairment of the axial vasculature at 24 hpf and absence of 
ISVs and a lack of blood circulation (not shown), indicating that etv2 morpholino 
knockdown was successful. Embryos were photoconverted at the 20-somite stage (19 hpf) to 
enable the assessment of the endothelial contribution to ISVs during the recovery period 
(Figure 2). Photoconversion at the 20-somite stage in control embryos resulted in 97% 
(n=91 of 95) of trunk ISVs exhibiting both red and green fluorescence (Figure 2A), 
indicating that a majority of cells contributing to the ISVs in WT embryos were specified 
before the 20-somite stage, as we have previously reported.41 Morphants showed a partial 
recovery of axial and intersegmental vasculature by 36 hpf, but the average number of 
fluorescent ISVs per fish was significantly reduced relative to WT controls (2.1±0.3 in 
morphants versus 7.3±0.3 in controls, Figure 2B). Because vascular expression in 
etv2:Kaede embryos was mosaic, only a fraction of the total number of ISVs exhibited 
fluorescence. Ninety percent of the ISVs in the morphant embryos were both red and green 
(n=40 of 46), arguing that the angiogenic recovery in control and morphant embryos was 
also largely mediated by VECs present before the photoconversion period. Occasionally, 
green only cells were detected in the vascular plexus of both WT and morphant embryos at 
36 hpf, providing confirmation that new VECs had formed, but these new cells did not 
significantly contribute to the observed recovery. It is likely that red fluorescence was not 
apparent in some of the green cells because of faint fluorescence and turnover of the 
photoconverted Kaede protein. Photoconversions performed before the 20-somite stage were 
uninformative because converted Kaede expression was not detectable through the target 
angiogenic recovery period because of weak etv2:Kaede expression during early stages (data 
not shown).
Loss of fli1b Exacerbates the etv2 Vascular Phenotype
We hypothesized that other ETS transcription factors function redundantly with Etv2 during 
the later stages of vascular development to mediate the vascular recovery observed in etv2 
mutants and morphants. Three related ETS factors Ets1, Fli1a and Fli1b have been 
previously implicated as having a redundant function with Etv2.29 However, the previous 
study used a month-only approach without stringent controls, such as RNA rescue. 
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Furthermore, the individual roles of each of these transcription factors have not been 
determined, and only limited phenotypic analysis has been previously performed. We 
focused our analysis on the 2 Fli1 homologs, Fli1a and Fli1b. As previously reported, strong 
expression of fli1a and fli1b continues in vascular endothelium past 24 hpf, whereas etv2 
expression becomes greatly reduced29,36 (Figure IA through IK in the online-only Data 
Supplement). Furthermore, fli1b expression was significantly reduced but detectable by 
whole-mount in situ hybridization in etv2 mutants from 24 hpf through 36 hpf (Figure IL 
and IM in the online-only Data Supplement), suggesting that fli1b expression occurs in an 
etv2-independent manner throughout the recovery period of etv2-deficient embryos.
Fli1a and fli1b mutant lines were generated in Tol2-mediated insertional mutagenesis 
screens. The fli1ais10Gt mutant line contains a gene trap vector insertion in the third intron of 
fli1a gene with a splice acceptor site followed by enhanced green fluorescent protein (GFP) 
and polyA sequence (Figure IIA in the online-only Data Supplement). The insertion causes a 
truncation of the sterile alpha motif/pointed protein-binding domain, and the resulting Fli1a 
protein is predicted to lack the C-terminal ETS DNA-binding domain (Figure IIB in the 
online-only Data Supplement). The insertion resulted in 21.3-fold reduction in expression of 
full-length message as determined by reverse transcription polymerase chain reaction 
(Figure IIL in the online-only Data Supplement) and whole-mount in situ hybridization 
using an antisense probe against the 3′ end of the message containing the ETS-binding 
domain (Figure III and IIJ in the online-only Data Supplement). Fluorescence of the 
truncated fli1ais10Gt-GFP fusion protein was evident in the vascular endothelium, detectable 
by the 10-somite stage (14 hpf), and vascular-restricted expression was observed throughout 
embryogenesis (Figure UK in the online-only Data Supplement and data not shown). A 
gene-trap fli1btpl50Gt mutant line was generated in a Tol2-mediated insertional mutagenesis 
screen using GBT-B4 gene trap vector (C. Seiler et al, unpublished data, 2015) similar to the 
recently published GBT-B1.42-44 The gene trap transposon (Figure IIE in the online-only 
Data Supplement) integrated into the first intron and near the start of the coding sequence 
resulting in a Gal4-VP16 fusion protein lacking the ETS DNA-binding domain (Figure IIF 
through IIH in the online-only Data Supplement); therefore, the mutation is expected to be 
null or severe hypomorph.43 Consistent with this view, the gene-trap disruption resulted in 
an 18.5-fold (5.4±2.0%) reduction in full-length fli1b message as determined by reverse 
transcription polymerase chain reaction and whole-mount in situ hybridization (Figure IIM, 
IIN, and IIP in the online-only Data Supplement). RNA-Seq also confirmed significant 
reduction of terminal exon 9 reads of fli1b (2.4±2.6%, n=2 samples of 20 embryos, age 24 
hpf, read at a depth of 20 million reads per sample). Gene trap embryos exhibited high levels 
of vascular endothelial GFP reporter expression beginning at the 12-somite stage (15 hpf), 
vascular restricted at 48 hpf (Figure IIO in the online-only Data Supplement), and 
maintained into adulthood (data not shown). In stark contrast to the previous study using 
morpholinos,29 fli1ais10Gt or fli1btpl50Gt mutant embryos had no apparent defects in vascular 
development (Figure IIK and IIO in the online-only Data Supplement) or vascular marker 
expression (Figure III in the online-only DataSupplement). Homozygous Fli1ais10Gt and 
Fli1btpl50Gt mutants (referred to as Fli1a-/- and fli1b-/-) developed normally into adulthood 
with no overt effect on growth or fecundity.
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To assess the potential interaction between etv2 and the fli1a and fli1b ETS factors, we used 
etv2 morpholino knockdown in the corresponding mutant lines. Fli1a mutant embryos were 
injected with etv2 MO at the 1-cell stage (0.2 hpf) and imaged at stages from 24 to 72 hpf. 
Double fli1a-/-; etv2 MO embryos were indistinguishable from etv2 morphant embryos 
(Figure IV in the online-only Data Supplement), thus suggesting that the loss of Fli1a did 
not significantly enhance on the etv2 morphant phenotype. In contrast, the vascular 
phenotype associated with etv2 morpholino knockdown alone (Figure 3A-3D) was clearly 
exacerbated in fli1b+/- embryos (Figure 3E-3H) and further impaired in fli1b-/- embryos 
(Figure 3I-3L). Flilb+/- and fli1b-/- embryos with etv2 morpholino knockdown were easily 
distinguishable from etv2 morphant embryos by 24 hpf because of a reduction in the number 
of GFP-positive VECs when compared with etv2 morphant embryos (Figure 3E and 3I). 
Although endothelial cells in etv2 morphants coalesced to form the axial vasculature by 24 
hpf, angioblasts in etv2 MO;fli1b-deficient embryos remained dispersed. At 36 hpf, both 
etv2 MO;fli1b+/- and etv2 MO;fli1b-/- embryos completely lacked intersegmental sprouts and 
showed a reduced number of GFP-positive cells relative to etv2 morphants. At 48 hpf, a few 
intersegmental sprouts were observed in the anterior trunk of etv2 MO;fli1b+/- (Figure 3G) 
but not in etv2 MO;fli1b-/- embryos (Figure 3K), which we interpret as a dose-effect 
resulting from the loss of functional fli1b protein. By 72 hpf, etv2 morphants exhibited a 
significant recovery in both the axial and ISVs (Figure 3D), whereas embryos also 
heterozygous for the fli1b gene trap displayed only a moderate recovery of the axial vessels 
and sporadic ISVs in the anterior trunk region (Figure 3). Finally, etv2 MO;fli1b-/- embryos 
showed a persistent gap in the axial vessels (Figure 3J–3L, arrow), indicating further 
impaired vasculogenesis. These embryos did not undergo angiogenic sprouting (Figure 3L), 
and their vasculature remained largely unchanged until they died at 5 dpf (data not shown). 
Because of the close proximity of etv2 and fli1b genes within the zebrafish genome, it was 
not possible to obtain the double etv2;fli1b-/- mutants using a simple cross because of the 
expected low frequency of recombination between the 2 genes. Nevertheless, etv2 MO has 
been validated in multiple previous studies and results in the same vascular phenotype as 
etv2-/- null mutants (Figures 1 and 3). We also tested whether double heterozygous 
etv2+/-;fli1b+/- mutants showed any vascular defects. Etv2+/-;fli1b+/- double heterozygous 
embryos were indistinguishable from WT embryos and did not display any defects in 
vascular patterning (Figure VA in the online-only Data Supplement).
We and others have previously reported a strong loss of multiple vascular endothelial 
marker expression observed in etv2 morphant and mutant embryos at 24 hpf.22,29 By 36 hpf, 
a partial recovery of the endothelial marker expression was observed in etv2 mutant and 
morphant embryos (Figure 4), consistent with the partial recovery of ISV sprouting observed 
in etv2 morphants. However, no significant vascular marker recovery was observed in 
embryos deficient in both etv2 and fli1b, and expression of the cdh5, fli1a, flt4, and kdrl 
vascular markers was largely undetectable through 36 hpf. Interestingly, a bilateral 
population of etv2-positive cells located in the trunk was retained in double-knockdown 
embryos, potentially representing a population of nondifferentiated etv2-positive vascular 
endothelial progenitors. Taken together, these data argue that Fli1b is capable of supporting 
vascular development in the absence of etv2 and that it participates in the angiogenic 
recovery of etv2-deficient embryos.
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We also tested whether double fli1a-/-;fli1b-/- mutants showed any vascular defects. 
However, vascular patterning in fli1a-/-;fli1b-/- mutant embryos was normal (Figure VB in 
the online-only Data Supplement). fli1a-/-;fli1b-/- embryos exhibited impaired circulation at 
32 hpf (not shown) and pericardial edema at 48 hpf, and the vessels appeared to fail to 
lumenize. Although the primary cause of this phenotype needs furtfromWTher investigation, 
these results show that the initial vasculogenesis and angiogenesis proceed normally in the 
absence of fli1a and fli1b functions.
Etv2 and fli1b Function in a Redundant Manner to Support Angiogenesis
The complete lack of angiogenic recovery observed in etv2 MO;fli1b-/- mutant embryos 
could be attributed to a direct requirement for etv2 and fli1b in angiogenesis or an indirect 
consequence of the failed vasculogenesis observed in etv2 MO;fli1b-/- mutant embryos. To 
determine whether etv2 and fli1b contribute combinatorially to sprouting angiogenesis, we 
used a previously validated photoactivatable (ie, caged) etv2 morpholino41 to block 
endogenous etv2 function at selected stages. Early photoactivation at 50% epiboly (5.3 hpf) 
confirmed effective uncaging and morpholino function as evidenced by a complete absence 
of angiogenesis at 24 hpf (data not shown). Fli1a:GFP expression at 42 hpf was robust in 
control embryos (Figure 5A), whereas embryos which were injected with the caged MO and 
uncaged at the 50% epiboly stage exhibited a partial recovery of the ISVs (Figure 5B), 
consistent with standard morpholino results (Figure 3B). Etv2-caged MO–injected embryos 
uncaged at the 18-somite stage (18 hpf) appeared grossly normal (Figure 5C) and were 
indistinguishable from control embryos that were injected with caged etv2 MO and never 
uncaged (Figure 5D). GFP fluorescence in 42 hpf fli1b-/- embryos (Figure 5E) mirrored the 
vascular-specific expression observed in the fli1a:GFP line (Figure 5A). Fli1b homozygous 
mutant embryos that were injected with the caged MO and uncaged at the 50% epiboly stage 
exhibited a more pronounced vascular phenotype relative to uncaged etv2 morphants in a 
WT background (Figure 5F compared with Figure 5B), as expected. Fli1b mutant embryos 
uncaged at the 18-somite stage showed a clear impairment of sprouting angiogenesis at 42 
hpf (Figure 5G) compared with their never uncaged controls (Figure 5H). In these embryos, 
the axial vessels formed normally, but no complete ISVs and only partial ISVs were 
observed in the imaged portion of the trunk (average of 14±4 partial ISVs), compared with 
24±0 fully formed ISVs in the corresponding caged etv2 morphants (Figure 5C). These 
results indicate that both etv2 and fli1b are redundantly required for angiogenesis 
independent from the etv2 earlier role in vasculogenesis.
Embryos Deficient in Both Etv2 and Fli1b Have an Expanded Zone of Apoptosis During 
Vasculogenesis
Because embryos deficient in both Etv2 and Fli1b exhibited a dramatic reduction in the 
number of VECs, particularly in the axial vasculature, we sought to determine whether this 
deficiency was because of increased apoptosis. Minimal caspase 3 staining was observed in 
WT embryos (Figure 6A), whereas etv2 morphant embryos showed increased apoptosis all 
along the axial vasculature (Figure 6B), similar to previous reports.29 Apoptotic staining in 
fli1b-/- embryos was not significantly different from WT embryos (Figure 6C). Staining was 
significantly expanded in etv2 MO;fli1b-/- embryos into the trunk axial vasculature (Figure 
6D), suggesting that the observed reduction in VEC number was because of apoptotic cell 
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death, either as a direct result of combined Etv2 and Fli1b loss or as an indirect consequence 
of impaired VEC differentiation. Cyclopamine induction of apoptosis was used to confirm 
caspase 3 staining, and a no antibody control was used to confirm a lack of nonspecific 
staining (data not shown). However, little overlap between endothelial GFP and caspase 
staining was detected. To rule out the possibility that the caspase-positive cells were 
primitive erythrocytes that originate in the adjacent LPM, we performed heme staining (data 
not shown) and whole-mount in situ analysis for hematopoietic markers hbbe3 and gata1 
that were not changed in etv2 MO;fli1b-/- embryos (Figure 6A′-D′ and A″-D″), thus 
indicating that primitive erythropoiesis is normal in etv2 MO;fli1b-/- embryos. We repeated 
caspase 3 staining at earlier 10-somite (14 hpf) and 20-somite (19 hpf) stages. In both cases, 
caspase 3 staining was observed in the LPM, but no costaining with fli1a:GFP was observed 
(data not shown). We thus conclude that the vascular endothelial progenitors undergo 
apoptosis before they can initiate fli1a:GFP expression.
Etv2 and fli1b Can Independently Induce Vascular Endothelial Marker Expression
Previous studies have shown that etv2 overexpression is sufficient for the specification of 
endothelial and myeloid but not the erythroid lineages.22,23,27 To determine whether these 
functional roles also hold true for fli1a and fli1b, sense mRNA was injected into WT 
embryos. Overexpression of fli1a had no effect on the expression of vascular endothelial 
markers kdrl, fli1b, or etv2, hemangioblast marker scl, or erythroid marker gata1 expression 
(Figure VI in the online-only Data Supplement). In contrast, overexpression of fli1b mRNA 
induced ectopic expression of the vascular endothelial kdrl:GFP reporter and fli1a marker 
(Figure 7B and 7D). Also consistent with the published function of etv2,22 fli1b 
overexpression induced the early hemangioblast marker scl (Figure 7F) but had no effect on 
the erythroid marker gata1 (Figure 7H), thus arguing that fli1b overexpression is sufficient 
to induce vascular endothelial differentiation, similar to Etv2. To determine the relationship 
between etv2 and fli1b, a series of epistatic interaction analyses were performed. 
Overexpression of etv2 caused ectopic expression of fli1b (Figure 7J), and conversely, 
overexpression of fli1b was sufficient to induce expression of etv2 (Figure 7L), suggesting 
that a positive feedback relationship potentially exists between the 2 transcription factors.
To determine whether fli1b was capable of inducing vascular marker expression in the 
absence of functional etv2, fli1b sense mRNA was injected into embryos from an etv2+/- 
Tg(fli1a:GFP) carrier in-cross. Robust expression of the downstream vascular marker fli1a 
was observed in the endothelial progenitor cell pools of WT embryos (Figure 7M) but was 
restricted to nonendothelial group of cells in the presumptive pharyngeal endoderm region in 
12-somite (15 hpf) etv2 homozygous mutant embryos (Figure 7N). Embryos obtained from 
the etv2+/- carrier in-cross and injected with fli1b mRNA showed strong ectopic expression 
of fli1a:GFP (Figure 7O), thereby arguing that fli1b is capable of inducing the vascular 
marker fli1a expression independent of etv2 function.
Cloche mutant zebrafish are deficient in both endothelial and hematopoietic lineages,45 and 
etv2 is reduced in cloche mutants,46 suggesting that cloche is required for the differentiation 
of the hemangioblasts and functions upstream of etv2. Etv2 overexpression in cloche 
mutants is sufficient to induce expression of vascular markers, such as kdrl/flk1/VegfR2.22 
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We found that overexpression of fli1b in cloche mutant embryos also caused ectopic 
expression of kdrl (Figure 7P through 7R), suggesting that fli1b is also downstream of 
cloche and is sufficient to initiate vascular endothelial differentiation. Taken together, our 
data show that etv2 and fli1b, but not fli1a, are capable of inducing a similar set of vascular 
endothelial markers, which suggests that etv2 and fli1b may have an overlapping function.
Etv2 and Fli1b Have a Combinatorial Effect on Multiple Vascular Endothelial Markers
RNA-Seq analysis was performed on 24- and 48-hpf embryos to profile gene expression 
changes in etv2 morphant, fli1b-/-, and etv2 MO;fli1b-/- embryos. As expected, the 
expression of multiple vascular endothelial markers was significantly reduced in etv2 
morphant embryos at 24 hpf and partially recovered at 48 hpf, consistent with the partial 
angiogenic recovery observed in morphant embryos (Table). Vascular markers were largely 
normal in fli1b mutant embryos, as expected, because these embryos develop a normally 
appearing vasculature. Vascular markers were further reduced in double-deficient embryos 
(Table), consistent with the severe vascular deficit in these embryos. Interestingly, most of 
the endothelial markers partially recovered by 48 hpf in the double-deficient embryos (as 
observed in the etv2 morphant embryos), despite the lack of an angiogenic recovery in these 
embryos. Of note, etv2 was significantly increased at 24 hpf in etv2 morphant embryos and 
double-deficient embryos (confirming in situ analysis shown in Figure 4). Etv2 levels were 
further increased in morphants during the angiogenic recovery occurring at 48 hpf, but no 
further increase was observed in double-deficient embryos, consistent with the failed 
angiogenic recovery observed in these embryos.
Further analysis of our RNA-Seq data (Table) provided additional insight into the role 
played by fli1b relative to etv2 and fli1a. Fli1a message was reduced 1.3-fold in etv2 
morphants and further reduced (down 2.45-fold) in etv2 MO;fli1b-/- embryos at 24 hpf, 
suggesting that Etv2 and Fli1b are involved in regulating fli1a expression.
Fli1b Directly Induces Fli1a Expression
Etv2 binds together with FoxC homologs to the FOX-ETS motif present within the 
promoters of multiple vascular endothelial–specific genes.28 Evolutionarily conserved ETS 
sites have been identified within the proximal mouse Fli1 and zebrafish Fli1 a promoters 
with direct binding of Etv2 to these sites shown.34,47 Putative ETS-binding sites 
corresponding to the functional murine ETS sites were identified in the zebrafish fli1a 
promoter (Figure VIIA in the online-only Data Supplement). In addition, a conserved FOX-
ETS motif with several adjacent ETS motifs was identified within the first intron of fli1a 
gene (Figure VII in the online-only Data Supplement). All of these identified sites are 
present within the fli1a[ep] enhancer–promoter region, which has been previously 
demonstrated to be necessary and sufficient for vascular endothelial reporter expression.47 
To determine whether Fli1b directly binds to the DNA fragments containing these consensus 
binding sites, we performed chromatin immunoprecipitation analysis on zebrafish embryos 
injected with FLAG-fli1b RNA. Overexpression of FLAG-tagged fli1b, similar to the 
overexpression of untagged fli1b, resulted in specific induction of vascular endothelial 
markers, including fli1a:GFP. Embryos were fixed at the tailbud stage and subjected to 
chromatin immunoprecipitation using FLAG antibody. Specific enrichment for 2 fragments, 
Craig et al. Page 10













containing the previously described ETS sites within the proximal fli1a promoter (2.27±0.80 
fold enrichment) and a consensus FOX-ETS site within the first intron of fli1a (4.62±1.64 
fold enrichment), was observed. Multiple other genomic regions tested showed no 
enrichment in the pull down fraction (data not shown), which argues for the specificity of 
the observed binding.
Functional activity of the predicted ETS-binding sites was verified by cloning the fli1a[ep] 
enhancer–promoter region upstream of an enhanced GFP reporter and evaluating the ability 
of fli1b mRNA to induce reporter expression (Figure VIIIA in the online-only Data 
Supplement). All predicted ETS-binding sites within the fli1a[ep] promoter–enhancer were 
mutated to test their functional requirement (Figure IX in the online-only Data Supplement). 
Control injections of the reporter fli1a[ep]:GFP construct with etv2 mRNA yielded ectopic 
GFP expression at the 8-somite stage (13 hpf) in 44% of embryos (n=192). Mutation of the 
ETS-binding sites in the fli1a[ep]:GFP reporter construct blocked its induction by etv2, thus 
indicating that etv2 induced expression in an ETS-binding site–dependent manner. 
Coinjection of the reporter construct with fli1b mRNA induced GFP reporter expression in 
61% of embryos (n=184). Because we had already demonstrated that Fli1b injection induces 
etv2 expression, we used etv2 MO to inhibit Etv2 function and to test fli1b activity directly. 
When the fli1a[ep]:GFP construct was coinjected with etv2 MO and fli1b mRNA, strong 
ectopic GFP expression was observed in 64% (n=170) of embryos, indicating that Fli1b is 
capable of activating fli1a[ep] promoter in the absence of etv2 (Figure VIIIB and VIIIC in 
the online-only Data Supplement). Injections made with the enhanced GFP reporter 
construct lacking predicted ETS-binding sites yielded no fluorescent embryos (n=146), 
indicating that ETS sites are required for induction of fli1a[ep]:GFP by Fli1b. In summary, 
these results argue that Fli1b directly induces expression of fli1a by binding to the ETS-
binding sites within the fli1a promoter–enhancer.
Discussion
In this study, we describe a novel critical function for 2 related ETS transcription factors 
Etv2 and Fli1b in initiating angiogenesis and completing vasculogenesis during early 
embryonic development. The data presented herein are consistent with a model of 
embryonic vascularization in which etv2 initiates the vascular endothelial program 
(including expression of fli1a, fli1b, and related markers) during early vasculogenesis, and 
later etv2 and fli1b are redundantly required during late vasculogenesis and early sprouting 
angiogenesis (Figure 8). During early stages of vascular development (1–15 somite stages), 
zebrafish etv2 single mutants display essentially complete lack of VECs and have little if 
any vascular endothelial marker expression; therefore, Etv2 seems to be the single major 
master regulator of early vasculogenesis. The lack of a vascular phenotype in fli1a and fli1b 
double-mutant embryos suggests that both Fli1a and Fli1b are largely dispensable for early 
vasculogenesis in WT embryos. However, etv2 mutants do form vascular endothelial 
progenitors at later stages and initiate angiogenesis after 36 hpf. Only double-deficient 
etv2;fli1b embryos show persistent loss of vascular endothelial progenitors within the axial 
vasculature and complete absence of angiogenesis during 24 to 72 hpf. This argues for the 
functional redundancy between Etv2 and Fli1b during these stages of late vasculogenesis 
and early angiogenesis (Figure 8).
Craig et al. Page 11













In support of this model, the reduced endothelial cell numbers and gaps in the axial 
vasculature at later stages are only observed in double etv2;fli1b knockdown embryos, which 
argues that Etv2 and Fli1b function redundantly and that Fli1b responsible for mediating the 
angiogenic recovery observed in etv2 mutants and morphants. The compensatory supporting 
function of fli1b in etv2-deficient embryos is further supported by the induction of multiple 
vascular markers by Fli1b overexpression, including direct induction of fli1a by binding to 
ETS sites fli1a promoter–enhancer region.
Whole-mount in situ hybridization and reverse transcription polymerase chain reaction data 
presented here and elsewhere indicate that fli1b is expressed at low levels beginning at the 8-
somite stage (13 hpf) and then increases to a sustained plateau of high-level expression at 
around the 20-somite stage (19 hpf) when etv2 expression is waning.29,48 Because fli1b 
expression exceeds that of etv2 during the angiogenic recovery of both etv2 morphants and 
mutants (ie, after 24 hpf) and because Fli1b is capable of inducing the same vascular target 
genes as Etv2, it is likely that the angiogenic recovery observed in etv2-deficient embryos 
occurs through the compensatory action of fli1b. In this scenario, loss of Fli1b in etv2 
mutants would result in a failure of angiogenic sprouting altogether, as we observed. Our 
data do not exclude potential contribution from other vascular ETS factors (eg, Erg or 
Ets-1), as suggested previously,29 but the normal profile of vascular markers in fli1a mutants 
combined with the lack of vascular marker induction in fli1a injected embryos suggests that 
fli1a is not mediating the observed angiogenic recovery and thus serves a functional role, 
which is distinct from fli1b. It is possible that such a functional redundancy has evolved as a 
means of protecting the embryo from vascular development defects and that additional ETS 
factors have the capacity to support vascularization in the absence of the normally dominant 
etv2.
It has been previously reported that fli1a-/- and fli1b-/- single-MO knockdown embryos 
exhibit defects in ISV sprouting.29 Despite the profound loss of target gene expression in the 
fli1a and fli1b gene trap lines, we did not observe any apparent vascular patterning defects in 
either mutant line. Therefore, it is likely that some of the previously reported defects were 
caused by MO off-target effects. However, we cannot rule out the possibility that small 
amounts of WT transcript that remained in fli1a-/- and fli1b-/- lines were sufficient to allow 
normal development. An increased incidence of hemorrhages attributed to a loss of vessel 
integrity has been previously reported in fli1a MO knockdown zebrafish embryos,37 and in 
Fli1 mutant mice,33 but hemorrhages were not observed in fli1a-/- or fli1b-/- embryos.
Our observation that the failed angiogenic recovery in embryos deficient in Fli1b and Etv2 
correlated with an elevated level of apoptosis and a reduction in the number of VECs 
(relative to Etv2-deficiency alone) is consistent with other studies which have implicated 
ETS factors as modulators of apoptosis. Overexpression of human Fli1 and Erg inhibit 
apoptosis in vitro, thus providing critical insight into the progression of Ewing sarcoma.49 
Further, exogenous expression of both Ets-2 and PU.1 increase Bcl-x activation to inhibit 
apoptosis in macrophages.50 While it is possible that Etv2 and Fli1b directly serve to inhibit 
apoptosis in vascular progenitor cells, our data cannot rule out an indirect initiation of 
apoptosis as a mechanism to remove undifferentiated vascular progenitor cells which fail to 
differentiate in the double Etv2;Fli1b knockdown embryos.
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Previous studies have demonstrated that Etv2 directly binds to multiple endothelial 
enhancers and acts as a potent transcriptional regulator.28 We and others have also 
demonstrated that Etv2 overexpression results in strong upregulation of multiple vascular 
endothelial–specific genes.22,40,41. In this study, we report that Fli1b overexpression 
upregulates a subset of vascular endothelial and early hematopoietic markers in the same 
manner as Etv2. Furthermore, Fli1b is sufficient to induce vascular endothelial marker 
expression in Etv2 null and cloche mutant embryos. These results suggest that Fli1b and 
Etv2 bind to a similar set of transcriptional targets. RNA-Seq analysis seems to support this 
contention because double-knockdown embryos show a marked reduction in vascular 
markers compared with etv2 MO alone. Our analysis also indicates that fli1b directly 
induces fli1a expression in an ETS-binding site–dependent manner by binding to known 
Etv2-target ETS sites28,34 within the fli1a promoter and first intron. Further testing is 
required to identify additional direct transcriptional targets of Fli1b and to determine the 
extent of transcriptional target overlap with Etv2 in both vasculogenesis and angiogenesis.
Previous reports have shown that etv2 is significantly post-transcriptionally repressed by the 
let-7 family of micro-RNAs during the formation of the peripheral vasculature and that 
protein levels are drastically reduced shortly thereafter, as determined by immunostaining in 
WT embryos.48 By contrast, Fli1a and Fli1b are not predicted targets of the let-7 family, 
which could explain the persistent expression of both in later development. Despite the 
reduced expression of etv2 during angiogenesis, our data suggest that etv2 functions beyond 
its generally recognized role in vasculogenesis and acts in combination with fli1b in these 
later stages of angiogenesis (ie, 24–72 hpf). This later role is supported by caged morpholino 
knockdown of etv2 in fli1b mutant background, which caused impaired angiogenic sprouting 
in embryos with intact vasculogenesis (Figure 5). It is important to point out that limited 
ISV sprouting was observed in fli1b mutant embryos injected with caged etv2 MO and 
photoactivated at the 18-somite (18 hpf) stage, whereas earlier inhibition of Etv2 function in 
fli1b-/- mutant background resulted in the complete absence of ISVs. The partial sprouting 
observed in caged etv2 MO;fli1b-/- embryos after photoactivation at the 18-somite stage 
could be explained by the contribution of other vascular ETS factors that may also serve a 
compensatory role and support angiogenesis in the absence of etv2 function.
Data published previously34 and several lines of data presented herein suggest that Etv2 is 
the primary driver of early expression of the downstream target fli1a, including (1) reduced 
fli1a:GFP transgenic expression in etv2 morphants and mutants, (2) reduced fli1a expression 
in etv2-deficient embryos by in situ analyses, (3) failure of fli1a mutant embryos to 
recapitulate (or even enhance) the etv2 mutant phenotype, and (4) direct evidence of Etv2 
binding to fli1a promoter–enhancer in fluorescent reporter assays. However, the observation 
that fli1a:GFP transgene expression and fli1a message partially recovered by 48 hpf 
suggests that etv2 is not solely required for inducing fli1a in vivo. Rather, because fli1a is 
significantly reduced only in etv2 MO;fli1b-/- embryos and ectopic Fli1b induced expression 
of the fli1a[ep]:GFP reporter construct, it is possible that Etv2 and Fli1b act cooperatively to 
induce fli1a expression or that both bind to ETS sites within the fli1a[ep] sequence and that 
the contribution of each ETS factor is based on the temporal concentrations of each. 
Although beyond the scope of this study, it would be interesting, therefore, to see whether 
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etv2 MO knockdown further exacerbates the fli1a-/-;fli1b-/- mutant phenotype. Also, it is 
possible that additional transcription factors or cofactors not part of this study are required 
for sustained expression of fli1a. Interestingly, a recent study demonstrated that in mouse 
embryos, Etv2 initiates Fli1 expression, which is further maintained by Fli1 
autoregulation.34 Similarly, our results show that zebrafish Etv2 initiates fli1a and fli1b 
expression, and then Fli1b is further involved in maintaining fli1a and possibly its own 
expression. Our results do not exclude the possibility that Fli1a also participates in 
maintaining its own expression. Thus, it seems that transcriptional regulation of Etv2 and 
Fli1 expression is evolutionarily conserved.
Taken together, our data indicate that Etv2 and Fli1b have redundant roles during late 
vasculogenesis and early embryonic angiogenesis. It is also intriguing to consider the 
possibility that they are involved in the remarkably similar processes of adult 
neoangiogenesis or in pathological hypervascularization. Our findings demonstrate a novel 
role for ETS transcription factors in angiogenesis and eventually may lead to the design of 
improved therapeutics to enhance wound healing or block tumor-induced vascularization.
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Nonstandard Abbreviations and Acronyms
ETS E26 transformation-specific
GFP green fluorescent protein
ISV intersegmental vessel
MO morpholino
VEC vascular endothelial cell
LPM lateral plate mesoderm
WT wild-type
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The E26 transformation-specific transcription factor Etv2/Etsrp has been previously 
shown to function as a master regulator during early embryonic vasculogenesis. Here, we 
demonstrate that Etv2 has a previously unrecognized role in angiogenesis and late 
embryonic vascuologenesis and that this novel function is supported by the redundant 
activity of a related E26 transformation-specific factor, Fli1b. We demonstrate for the 
first time that knockdown of 2 E26 transformation-specific factors results in a complete 
absence of angiogenesis and nearly complete absence of vasculogenesis. We show that 
Fli1b, similar to Etv2, directly initiates transcription of multiple endothelial–specific 
genes and that Etv2 and Fli1b induce the expression of each other. Taken together, our 
findings argue that fli1b and etv2 function together as critical regulators of endothelial 
differentiation. We expect that our results will be highly significant in elucidating 
molecular mechanisms of vascular development.
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Etv2-/- mutants undergo a partial recovery of vasculogenesis and aberrant sprouting 
angiogenesis by 72 hpf. A-L, Lateral views of wild-type (WT) and etv2-/- mutant embryos in 
the Tg(fli1a:GFP) vascular reporter line. Fli1a:GFP expression was evident at the 9-somite 
stage (13.5 hpf) in WT embryos (A) and localized to the bilateral angioblasts of the anterior 
and posterior lateral plate mesoderm (ALPM and PLPM, respectively). Endothelial 
fli1a:GFP was not observed in etv2-/- mutant embryos at this stage (B), but an additional 
nonendothelial population of fli1a+ cells located in the presumptive pharyngeal endoderm 
was retained in etv2-/- mutant embryos (asterisks, A and B). The first sign of vascular 
recovery in etv2-/- mutant embryos was observed at 15-somites (17 hpf, arrow, D). Uniform 
pairs of intersegmental vessels (ISVs) were observed sprouting from fully lumenized dorsal 
aorta (DA) vessels at 24 hpf in WT embryos (E), whereas vasculogenesis remained aberrant 
and ISVs absent in age-matched etv2-/- mutants (F). Fully formed ISVs could be seen 
extending from the DA and posterior cardinal vein (PCV) and branching at their dorsal 
terminus to form the dorsal longitudinal anastomotic vessel (DLAV) by 36 hpf in WT 
embryos (G), whereas ISV sprouts in age-matched etv2-/- mutants were just starting to form 
(arrowheads, H). The regularly patterned ISVs observed in 48-hpf WT embryos (I) were 
disrupted in etv2-/- mutants, with a majority mispatterned (arrowheads, J). Continued 
recovery was observed at 72 hpf (L). Fractions indicate the number of embryos with the 
observed pattern of green fluorescent protein (GFP) expression (numerator) and the total 
evaluated (denominator).
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Vascular recovery in etv2 morpholino (MO)-injected etv2:Kaede embryos is mediated by 
vascular endothelial cells specified before the 20-somite stage. A and B, etv2:Kaede 
expression in the trunk of 36-hpf embryos after photoconversion at the 20-somite stage (19 
hpf). A, Control embryos developed intersegmental vessels (ISVs) which were almost 
exclusively both red and green indicating that cells contributing to ISVs were specified 
before the 20-somite stage in normally developing embryos. B, Etv2 morpholino knockdown 
in etv2:Kaede embryos reduced angiogenic sprouting, as expected. A majority of ISVs in 
etv2 morphant embryos were red+green (arrows), with a small number of green only ISVs 
(asterisk) observed. C, Etv2 knockdown did not cause a significant change in the number of 
green only ISVs. Error bars, +1SD. WT indicates wild-type.
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Fli1b functions redundantly with etv2 to support vascular development. A-D, Vascular 
recovery in etv2 morphant Tg(fli1a:GFP) embryos from 24 to 72 hpf (lateral views, anterior 
to the left). C and D, Etv2 morpholino knockdown delayed angiogenic sprouting (compare 
A with Figure 1E) and caused a large fraction of mispatterned intersegmental vessels (ISVs) 
in wild-type fli1a:GFP embryos. E-H, Limited vascular recovery in fli1b heterozygous, etv2 
morphant embryos visualized using enhanced green fluorescent protein fluorescence from 
the gene trap vector. The etv2 morphant phenotype was exacerbated by the loss of 1 fli1b 
allele with embryos exhibiting impaired vasculogenesis from 24 to 36 hpf (E and F), and a 
limited recovery of angiogenic sprouting by 72 hpf (H). I-L, No vascular recovery observed 
in fli1b homozygous mutant, etv2 morphant embryos. Loss of both fli1b copies caused a 
significant impairment in vasculogenesis (I-K) and completely blocked angiogenesis 
through 72 hpf (L). Note the significant reduction in the number of vascular endothelial cells 
and large gaps within the axial vasculature (bottom, arrows). Fractions indicate the number 
of embryos with >15 ISVs (full or partial, numerator) and the total evaluated (denominator).
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Expression of vascular markers is reduced in etv2 morphants and further reduced in embryos 
deficient in both fli1b and etv2. Whole-mount in situ hybridization (WISH) analysis 
performed on 36-hpf wild-type (WT) embryos shows strong expression of cdh5, fli1a, flt4, 
kdrl, and etv2 in the trunk vasculature. All vascular markers tested excluding etv2 itself were 
reduced in both etv2 morphants and etv2 mutants, and further reduced in double-knockdown 
embryos. A population of etv2-positive presumptive endothelial progenitor cells was 
retained in the double-knockdown embryos (arrow). Fractions indicate the number of 
embryos with the strong/low/no expression, excluding etv2 WISH panels for which the 
middle number indicates astrong but disorganized, breduced and disorganized or cstrong 
expression in a few remaining cells.
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Etv2 and fli1b are required for angiogenesis independently from Etv2 early requirement in 
vasculogenesis. A-D, Caged etv2 morpholino (MO) analyses in 42-hpf wild-type (WT) 
embryos in a Tg(fli1a:GFP) background (lateral views, anterior to the left). A, Vascular 
patterning was normal and all intersegmental vessels (ISVs) were complete in control 
(uninjected) WT embryos that underwent the 30-minute UV exposure. B, All ISVs were 
incomplete in embryos injected with the caged etv2 MO and uncaged at 50% epiboly (5.3 
hpf). Embryos uncaged at this stage showed truncated ISVs, typical for similarly staged 
morphants (compare with Figure 3B), thus confirming efficient morpholino uncaging. WT 
embryos uncaged at the 18-somite stage (C) were indistinguishable from the never uncaged 
embryos (D) indicating etv2 knockdown alone at 18-somites (18 hpf) did not block 
angiogenic sprouting. E-H, Caged etv2 MO analyses in 42-hpf fli1b-/- embryos visualized 
using the green fluorescent protein (GFP) expressed in the gene trap line. E, Fli1b mutants 
had a normally appearing vasculature. Uncaging at 50% epiboly in the fli1b mutant 
background again resulted in a more significant impairment of both vasculogenesis and 
angiogenesis (F) than observed in WT background (B). G, Uncaging of the etv2 MO at 18-
somites in a fli1b mutant background resulted in truncated ISV sprouts (with no full-length 
sprouts observed). D and H, Embryos which were injected with caged MO and never 
uncaged had normally patterned ISVs (ie, <2 mispatterned ISVs), thus confirming effective 
caging. Fractions indicate the number of embryos with the >15 full ISVs (numerator) and 
the total evaluated (denominator).
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Apoptosis of vascular endothelial cells is expanded in double Etv2;Fli1b-deficient embryos. 
A-D, Whole-mount immunohistochemical staining of 48-hpf embryos for caspase 3 and 
green fluorescent protein (GFP) expression. Lateral views shown with anterior to the left. 
No distinct zones of apoptosis were noted in wild-type (A) and fli1b-/- embryos (C). By 
contrast, etv2 morphant embryos showed a narrow zone of apoptosis in the vascular plexus 
(B). D, This zone of apoptosis was expanded in embryos deficient in both fli1b and etv2 
(arrows). Hbbe3 (A′-D′) and gata1 (A″-D″) levels determined by whole-mount in situ 
hybridization show normal erythrocyte staining in all groups indicating the observed 
apoptosis was not because of a loss of blood cells. Fractions indicate the number of embryos 
with the observed pattern of marker expression (numerator) and the total evaluated 
(denominator).
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Fli1b overexpression is sufficient to induce expression of vascular endothelial markers in 
wild-type (WT), etv2-/- and cloche mutant embryos. A, C, E, G, I and K, Uninjected 
controls. Whole-mount in situ analysis of embryos is shown in lateral view with anterior of 
embryo oriented left. A-H, Effect of fli1b overexpression on vascular and hematopoietic 
markers during the indicated stages. Fli1b induces kdrl:GFP (B), fli1a (D), and scl (F), but 
not gata1 (H). I-L, Lateral views of WT embryos injected with fli1b and etv2 mRNA. J, 
Fli1b overexpression induces ectopic etv2 in WT embryos. L, Conversely, fli1b 
overexpression induces ectopic etv2. The number of embryos with ectopic expression 
(numerator) and the total number evaluated (denominator) lower left panel, the age and 
injected mRNA in the bottom left, and gene probed by in situ in the upper right. M-O, 
Effect of fli1b overexpression in etv2-/- mutant embryos. An in-cross of etv2+/- 
Tg(fli1a:GFP) adults yielded the expected Mendelian ratio of phenotypically WT (M) and 
etv2-/- embryos (N) as determined by fli1a:GFP expression. O, 99% embryos injected with 
fli1b mRNA exhibited ectopic expression of fli1a, indicating that fli1b is capable of inducing 
vascular fli1a in the absence of etv2. P-R, Fli1b mRNA induces ectopic kdrl expression in 
cloche mutant embryos. An in-cross of cloche heterozygous adults yielded the expected 
Mendelian ratio of 10-somite stage (14 hpf) WT (P) and mutant (Q) embryos, based on the 
presence or absence of kdrl expression. Injection of fli1b mRNA induced ectopic expression 
of kdrl (R) indicating that Fli1b acts downstream of cloche.
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Proposed Etv2 and Fli1b roles in vasculogenesis and angiogenesis. During early 
vasculogenesis, Etv2 induces the expression of multiple vascular endothelial and 
hemangioblast genes including fli1a, fli1b, and others. During late vasculogenesis and early 
angiogenesis, Etv2 and Fli1b both function redundantly to upregulate expression of fli1a and 
other vascular target genes. WT indicates wild-type.
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